Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
By R. Walton, Kathleen A. Christie, Madelynn N. Whittaker, B. Kleinstiver. Science, 2020
1,040 citations recorded by the source corpus.
A PAMless base editor CRISPR-Cas DNA base editing typically requires a specific motif for targeting known as a protospacer-adjacent motif (PAM). This requirement limits the sequences within a genome that can be targeted. Walton et al. engineered specific variants of the Streptococcus pyogenes Cas9 enzyme named SpG and SpRY that could recognize and edit a wider array of PAMs. Using SpRY, the authors were able to correct previously uneditable mutations associated with human disease. Although off-target effects were observed for these engineered Cas enzymes at levels similar to those of the wild-type enzyme, depending on the context, these engineered enzymes widen the potential applications of precision genome editing. Science, this issue p. 290 Engineered Cas variants nearly eliminate the protospacer-adjacent motif requirement for DNA-targeting CRISPR enzymes. Manipulation of DNA by CRISPR-Cas enzymes requires the recognition of a protospacer-adjacent motif (PAM), limiting target site recognition to a subset of sequences. To remove this constraint, we engineered variants of Streptococcus pyogenes Cas9 (SpCas9) to eliminate the NGG PAM requirement. We developed a variant named SpG that is capable of targeting an expanded set of NGN PAMs, and we further optimized this enzyme to develop a near-PAMless SpCas9 variant named SpRY (NRN and to a lesser extent NYN PAMs). SpRY nuclease and base-editor variants can target almost all PAMs, exhibiting robust activities on a wide range of sites with NRN PAMs in human cells and lower but substantial activity on those with NYN PAMs. Using SpG and SpRY, we generated previously inaccessible disease-relevant genetic variants, supporting the utility of high-resolution targeting across genome editing applications.
Subfields: Insect Science, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/84609b61a82a11e3122a81b5bdae20a2822e577b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- C. Rudin
- F. Uddin
- T. Sen
Citations in the corpus
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future (2020, background): “PAM D1135L/S1136W/G1218K/E1219Q/R1335Q/T1337R NGN (47)”